Back

BMI shift and associated cardiometabolic risk factors in people with type 2 diabetes and obesity and/or overweight: a post hoc analysis from SURMOUNT-2

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Diabetes: a risk factor in heart disease Obesity ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Naveed Sattar

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Diabetes Mellitus influence in Lipoprotein(a) gene expression and association to coronary artery disease
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose contrasporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on arterial stiffness, coronary flow reserve and liver steatosis in diabetes
Doctor K. Katogiannis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Social vulnerability and disparities in incidence of diagnosed diabetes in the united states, 2004 to 2019
Doctor S. Ayanian (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Plasma proteomics of all-cause and cause-specific mortality in individuals with and without type 2 diabetes: Results from two population-based KORA cohorts
Miss H. Luo (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Prevalence and incidence of heart failure in patients with type 2 diabetes mellitus. Results of the prospective DIABET-IC study
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes: a risk factor in heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Cardiometabolic outcomes in patients with overweight and obesity undergoing weight loss trials : a network meta-analysis
thumbnail
Congress Presentation
Cardiovascular prevention with GLP1 agonists in high or very-high cardiovascular risk irrespective of diabetes.
thumbnail
Congress Presentation
Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources